Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe. Authors' reply
نویسندگان
چکیده
LINKED CONTENT This article is linked to Pol et al and Lampertico & Papatheodoridis papers. To view these articles, visit https://doi.org/10.1111/apt.16197 https://doi.org/10.1111/apt.16238
منابع مشابه
Treatment of Chronic Hepatitis B with Tenofovir
Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated 154 HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment ...
متن کاملPrediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
Background Until now, no risk score could predict hepatocellular carcinoma (HCC) in nucleos(t)ide analog (NA)-treated Asian patients. Methods We enrolled 1325 NA-naïve chronic hepatitis B patients with entecavir monotherapy for >12 months, with 883 and 442 patients randomly assigned to the development and validation groups, respectively, in the risk model. Results The cumulative probabiliti...
متن کاملIncreased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.
UNLABELLED Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high-risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical e...
متن کاملRisk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure
BACKGROUND Nucleos(t)ide analogues (NUCs) treatment can reduce the risk of hepatocellular carcinoma (HCC) development and recurrence in chronic hepatitis B (CHB) patients. However, the risk of recurrence in CHB patients who develop HCC despite NUC treatment remains unclear. METHODS 167 consecutive CHB patients receiving curative resection for HCC with NUC therapy after surgery were retrospect...
متن کاملThe assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact of interferon-alfa on the incidence of HCC is clearer in Asian patients and those with compensat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alimentary Pharmacology & Therapeutics
سال: 2021
ISSN: ['1365-2036', '0269-2813']
DOI: https://doi.org/10.1111/apt.16251